Top Losers

Proteon Therapeutics Inc (NASDAQ: PRTO) tumbled 74.3 percent to $2.55 after the company disclosed that it did not meet primary endpoint in PATENCY-1 trial. Inovalon Holdings Inc (NASDAQ: INOV) dropped 35.6 percent to $9.60 as the company cut its earnings and revenue guidance for full year...

Ophthotech Corp (NASDAQ: OPHT) shares dropped 84.5 percent to $6.01 after the company reported negative results in its Phase III OPH1002 and OPH1003 studies. The two combination trials in wet age-related macular degeneration (AMD) failed to meet primary endpoints. Performant Financial Corp (...

Sigma Designs Inc (NASDAQ: SIGM) shares dropped 30.7 percent to $5.38. Sigma Designs reported fiscal third-quarter net income of $221,000 on revenue of $62.7 million. OHA Investment Corp (NASDAQ: OHAI) shares fell 20.8 percent to $2.08 after the company reported Form 8-K filing. Powell...

  Barnes & Noble Education Inc (NYSE: BNED) dropped 14.5 percent to $9.91 after the company reported weak results for its second quarter. Cerecor Inc (NASDAQ: CERC) shares fell 13.4 percent to $1.32. Cerecor shares have dropped 57.18 percent over the past 52 weeks, while the S...

  Cerecor Inc (NASDAQ: CERC) shares tumbled 19.4 percent to $1.41 after the company disclosed that its CERC-501 Phase 2 study did not meet primary objective. Hudson Technologies, Inc. (NASDAQ: HDSN) shares dropped 16.1 percent to $6.68 after the company announced a $45 million...

  Retractable Technologies, Inc. (NYSE: RVP) shares tumbled 51 percent to $1.25. Retractable Technologies shares have dipped 30.59 percent over the past 52 weeks, while the S&P 500 index has increased 5.37 percent in the same period. CEL-SCI Corporation (NYSE: CVM) shares dropped...

  Aradigm Corporation (NASDAQ: ARDM) shares dropped 57.1 percent to $2.25. Aradigm disclosed that it has met primary and secondary endpoint in ORBIT-4. However, it missed ORBIT-3 primary and secondary endpoint. Heat Biologics Inc (NASDAQ: HTBX) shares tumbled 55.9 percent to $1.27...

  Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) shares tumbled 65.2 percent to $1.53 after the company announced it was discontinuing all its clinical RNAi programs. The company also announced plans to reduce workforce by 30 percent. Cerecor Inc (NASDAQ: CERC) shares tumbled 55...

  Nivalis Therapeutics Inc (NASDAQ: NVLS) shares tumbled 57.1 percent to $2.68 after the company reported it failed to demonstrate benefit in absolute change in predicted FEV1 or in Sweat Chloride Reduction at 12 weeks. The failed trial has prompted four Wall Street firms to downgrade...

  Skyline Medical Inc (NASDAQ: SKLN) shares dropped 19.3 percent to $3.50. Skyline Medical shares have jumped 20.08 percent over the past 52 weeks, while the S&P 500 index has gained 6.39 percent in the same period. Cancer Genetics Inc (NASDAQ: CGIX) shares declined 15.6 percent...

  Cellectar Biosciences Inc (NASDAQ: CLRB) shares tumbled 27.4 percent to $1.57 after the company reported the pricing of its $8,000,000 public offering. Juno Therapeutics Inc (NASDAQ: JUNO) dipped 26.4 percent to $21.98 as the company disclosed that it has placed JCAR015 Phase II...

  Amedica Corporation (NASDAQ: AMDA) shares declined 31.4 percent to $0.720. Amedica announced a new sales leadership and issued regulatory updates. The company named Dana Lyons as Vice President of Sales and Marketing. Opexa Therapeutics Inc (NASDAQ: OPXA) dropped 27.20 percent to $1...

  Wins Finance Holdings Inc (NASDAQ: WINS) shares tumbled 43.8 percent to $80.00. Wins Finance shares have jumped 1,460.09 percent over the past 52 weeks, while the S&P 500 index has gained 4.97 percent in the same period. Superconductor Technologies, Inc. (NASDAQ: SCON) shares...

  DryShips Inc. (NASDAQ: DRYS) shares dipped 67.7 percent to $23.56. DryShips announced a registered direct offering to raise roughly $20 million. The company says the cash will be used to pay down some of its massive debt load. In addition to the $20 million, the company says it may...

  Endologix, Inc. (NASDAQ: ELGX) shares dropped 24 percent to $7.47 as the company issued an update on Nellix PMA process. Endologix disclosed that the FDA has requested the company to provide a two-year patient follow-up data from the EVAS-FORWARD IDE study of Nellix System. Akers...